Home Takeda China Honored as Top Employer in China for Fifth Consecutive Year

Takeda China Honored as Top Employer in China for Fifth Consecutive Year

Jan 26, 2021 19:08 CST Updated 19:08
Takeda

Biopharmaceutical Manufacturer

Shanghai, January 26, 2021 /PRNewswire/ -- Recently, the Top Employers Institute, an internationally authoritative employer branding research organization, proudly announced its annual list. Takeda China was certified as a "Top Employer China 2021" for the fifth consecutive year, recognized for its outstanding performance in three key areas: continuous talent development and cultivation strategies, employer branding initiatives, and employee care management systems.

武田中国杰出雇主2021奖杯及证书
Takeda China Top Employer 2021 Trophy and Certificate

“Top Employer” is an authoritative certification created by the globally renowned Top Employers Institute. Established 30 years ago, the institute is dedicated to enhancing human resources practices and helping companies create a better workplace environment. To date, over 1,600 companies across 119 countries and regions have been awarded the annual Top Employer certification.[1]

Mr. Shan Guohong, President of Takeda China, stated, “I am deeply proud that Takeda has been honored as a ‘Top Employer in China’ for five consecutive years. At Takeda, we firmly believe that our employees are the key to success and are central to our practice”Patients FirstOne of the core elements of our commitment. In light of the severe global pandemic situation, Takeda places greater emphasis on employee health, well-being, and career development. By continuously building a diverse and inclusive organization and fostering an open and mutually trusting work environment, we are dedicated to creating an exceptional employee experience.”

People-Oriented: Caring for Employee Health

COVID-19Epidemic OutbreakTakeda China remains committed to safeguarding the health and safety of every employee and their families. It promptly established an epidemic response task force, which continues to closely monitor updates from government authorities and official health agencies, formulate corresponding emergency epidemic prevention plans, and communicate these measures to all staff through internal platforms. Meanwhile, Takeda China regularly distributes epidemic prevention supplies to all employees and implements flexible work arrangements to ensure efficient and orderly operations while prioritizing employee health and safety.

The Chinese Path to Talent Development and Cultivation

“Empowering Employees” is one of the core pillars of Takeda China’s employer brand proposition. Takeda China employs diverse approaches, such as job rotation and cross-departmental collaboration, to enable high-potential employees to fully leverage their skills and experience. With the implementation of Takeda China’s five-year plan and the subsequent expansion of the organization, the “Takeda Wants to See You” initiative was launched in 2020 to enhance communication and engagement between management and employees. Under this program, Takeda China’s leadership team traveled to various cities across the country to engage directly with cross-functional colleagues, listen to employee feedback, and foster greater team integration.

In 2020, Takeda globally launched its new corporate philosophy. Takeda China simultaneously introduced the “Takeda Style: Six Principles of Tian,” which highlights distinct Chinese characteristics. This initiative was rolled out from top to bottom, engaging everyone from management to employees in comprehensive learning programs, and was also integrated into the talent recruitment process. The aim is to shape the unique qualities of the Takeda China team, encompassing excellence, responsibility, professionalism, resilience, lifelong learning, and compliance. Leveraging the new corporate philosophy and the Takeda Style, Takeda China has attracted and united a group of like-minded partners to work together towards achieving Takeda’s next five-year plan and better serving patients in China.

Ms. Wang Youliang, Head of Human Resources at Takeda China, stated, “This prestigious honor serves as significant recognition and motivation for Takeda’s human resources efforts. Employer branding is a crucial component of Takeda’s overall talent strategy. Alongside the robust development of China’s healthcare industry,”More outstanding local talent will join TakedaWe will continue to invest in and build a premier employer brand, enabling every employee to experience Takeda’s workplace culture of diversity, inclusion, trust, and innovation, and to achieve a brilliant career at Takeda.”

[1] https://www.top-employers.com/zh/about-us/

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical (Tokyo Stock Exchange Code: 4502(NYSE: TAK) is a Japan-based, values-driven, R&D-focused global biopharmaceutical company. Takeda is committed to translating scientific advances into highly innovative medicines that safeguard patients’ healthy lives and brighter futures. The company focuses on drug development in four therapeutic areas—oncology, gastroenterology, neuroscience, and rare diseases—and makes targeted R&D investments in plasma-derived therapies and vaccines. By pursuing highly innovative drug development, pioneering novel treatment approaches, and strengthening its collaborative R&D engine, Takeda builds a robust and diverse product pipeline to help improve people’s lives. With employees in approximately 80 countries and regions, Takeda works alongside local healthcare partners to deliver health benefits to patients worldwide.

Takeda entered China in 1994. Takeda China’s headquarters is located in Shanghai, with its main business centers on the Chinese mainland situated in Beijing, Shanghai, Tianjin, Guangzhou, and the Hong Kong Special Administrative Region. The company has established offices in major cities across China and currently employs more than 2,000 people in the country. With China’s economic development and the growing demand for healthcare, China has become one of Takeda’s most important emerging markets globally.

For more information, please visithttps://www.takeda.com 

Forward-Looking Statements

This manuscript and any materials distributed in connection therewith may contain forward-looking statements, views, or opinions relating to Takeda’s future business, future conditions, and operating performance, including Takeda’s estimates, forecasts, targets, and plans. Forward-looking statements often include, but are not limited to, words such as “aim,” “plan,” “believe,” “hope,” “continue,” “anticipate,” “intend,” “ensure,” “will,” “may,” “should,” “would,” “might,” “expect,” “estimate,” “forecast,” or similar expressions or their negative forms.

The forward-looking statements in this document are based solely on Takeda’s estimates and assumptions as of the date of publication. Such forward-looking statements do not constitute any guarantee by Takeda or its management regarding future performance and involve known and unknown risks, uncertainties, and other factors, including but not limited to: economic conditions affecting Takeda’s global operations, including the macroeconomic environments in Japan and the United States; competitive pressures and developments; changes in applicable laws and regulations; the success or failure of product development projects; decisions by regulatory authorities or the timing thereof; fluctuations in interest and exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the timing and impact of post-merger integration efforts for acquired companies; and the ability to divest assets non-core to Takeda’s operations and the timing of any such divestitures. All of these factors may cause Takeda’s actual results, performance, achievements, or financial condition to differ materially from any future results, performance, achievements, or financial condition expressed or implied by such forward-looking statements.

For more information on the above and other factors that may affect Takeda’s results, performance, achievements, or financial condition, please refer to “Item 3. Key Information—D. Risk Factors” in Takeda’s most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission, as well as other reports. For details, please visit Takeda’s website.https://www.takeda.com/investors/reports/sec-filings/orwww.sec.govTakeda’s future results, performance achievements, or financial position may differ materially from those expressed or implied by the forward-looking statements. Recipients of this press release should not place undue reliance on any forward-looking statements. Takeda has no obligation to update any forward-looking statements contained in this press release or any other forward-looking statements that the Company may issue, except as required by law or securities exchange regulations. Past performance is not indicative of future results, and Takeda’s performance described in this press release neither represents nor constitutes an estimate, forecast, or projection of Takeda’s future performance.